Efficacy and Safety of Basal Insulin Glargine Combination With Exenatide Bid vs Aspart30 in T2DM

NCT02467920 · clinicaltrials.gov ↗

PHASE4

Phase

COMPLETED

Status

349

Enrollment

OTHER

Sponsor class

Conditions

Type 2 Diabetes Mellitus

Interventions

DRUG: glargine + exenatide
DRUG: aspart 30

Sponsor

Huazhong University of Science and Technology